JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Garreau, L.
Right arrow Articles by Chalon, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Garreau, L.
Right arrow Articles by Chalon, S.

Vol. 282, Issue 1, 467-474, 1997

N-(3-Iodoprop-2E-enyl)-2beta -carbomethoxy-3beta -(3',4'-dichlorophenyl)nortropane (beta -CDIT), a Tropane Derivative: Pharmacological Characterization as a Specific Ligand for the Dopamine Transporter in the Rodent Brain1

Lucette Garreau, Patrick Emond, Catherine Belzung, Denis Guilloteau, Yves Frangin, Jean-Claude Besnard and Sylvie Chalon

INSERM U316, Laboratoire de Biophysique Médicale et Pharmaceutique, 37200 Tours, France (L.G., P.E., D.G., Y.F., J.-C.B., S.C.), and Laboratoire d'Ethologie et de Pharmacologie du Comportement, Faculté des Sciences, 37200 Tours, France (C.B.)

N-(3-Iodoprop-2E-enyl)-2beta -carbomethoxy-3beta -(3',4'-dichlorophenyl)nortropane (beta -CDIT), a new iodinated tropane derivative, has been synthesized and radiolabeled with iodine. [125I]beta -CDIT was tested in vitro and ex vivo as a probe for the dopamine transporter site in the rat brain, and behavioral studies were performed in mice. Saturation studies in the striatum revealed that [125I]beta -CDIT bound to a single high-affinity site. The Kd value was 0.18 ± 0.07 nM, and the corresponding Bmax value was 500 ± 80 fmol/mg of protein. The pharmacological profile of specific [125I]beta -CDIT binding in the striatum was consistent with that of the dopamine transporter. In addition, competition studies in cerebral cortex regions with [3H]paroxetine and [3H]nisoxetine showed a very low affinity of beta -CDIT for the 5-hydroxytryptamine (Ki = 50 nM) and norepinephrine (Ki = 500 nM) transporters compared with beta -CIT (corresponding Ki values were 3 and 80 nM). In contrast, the competition of beta -CDIT with [3H]GBR 12935 in the striatal region (Ki = 29 nM) was of the same order of value as for beta -CIT (Ki = 27.5 nM). Behavioral experiments in mice showed that both beta -CDIT and beta -CIT induced stimulation of locomotor activity. Ex vivo autoradiographic studies in rats using [125I]beta -CDIT demonstrated high densities of [125I]beta -CDIT binding sites in areas known to be rich in dopaminergic innervation. Because of its high affinity and high selectivity for the dopamine transporter, [125I]beta -CDIT should be a valuable ligand for the exploration of the dopamine transporter with single-photon emission computed tomography.


Copyright © by The American Society for Pharmacology and Experimental Therapeutics






Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1997 by the American Society for Pharmacology and Experimental Therapeutics.